Journal of Neurology

, Volume 258, Issue 7, pp 1197–1206 | Cite as

Immunizations and risk of multiple sclerosis: systematic review and meta-analysis

  • Mauricio F. Farez
  • Jorge CorrealeEmail author


The role of vaccinations in risk of developing multiple sclerosis (MS) or in risk of relapse has not been well established. The aim of this study was to estimate the effect of immunizations on risk of developing MS in adults as well as in subsequent risk of relapse. Systematic search for publications in MEDLINE (1966–January 2011), EMBASE (1977–January 2011) and the Cochrane Central Register of Controlled Trials (CENTRAL) (1961–January 2011). Both randomized clinical trials and non-randomized studies addressing the effect of any Center for Diseases Control (CDC) recommended vaccine for children, adults or travelers and BCG on risk of MS or disease relapse were included. Two reviewers independently extracted information from articles selected using a predefined datasheet. No significant change in the risk of developing MS after vaccination was found for BCG (OR 0.96, 95% CI 0.69–1.34), Hepatitis B (OR 1.00, 95% CI 0.74–1.37), Influenza (OR 0.97, 95% CI 0.77–1.23), Measles–Mumps–Rubella (MMR) (OR 1.02, 95% CI 0.64–1.61), Polio (OR 0.87, 95% CI 0.61–1.25) and Typhoid fever (OR 1.05, 95% CI 0.72–1.53). We found decreased risk of developing MS for Diphtheria (OR 0.60, 95% CI 0.40–0.90) and Tetanus (OR 0.68, 95% CI 0.54–0.84). Influenza immunization was also associated with no change in risk of MS relapse (RR 1.24, 95% CI 0.89–1.72). Risk of developing multiple sclerosis remained unchanged after BCG, Hepatitis B, Influenza, MMR, Polio and Typhoid fever immunization, whereas diphtheria and tetanus vaccination may be associated with a decreased risk of MS. Further research is needed for the remaining vaccines.


Multiple sclerosis Systematic review Meta-analysis Vaccines 



This study was supported by funding from the Raúl Carrea Institute for Neurological Research, FLENI.

Conflict of interest


Supplementary material

415_2011_5984_MOESM1_ESM.doc (338 kb)
Supplementary material 1 (DOC 338 kb)
415_2011_5984_MOESM2_ESM.pdf (476 kb)
Supplementary material 2 (PDF 476 kb)


  1. 1.
    WHO (2005) Immunization against diseases of public health importance. World Health Organization (WHO). Accessed 25 Aug 2010
  2. 2.
    Doja A, Roberts W (2006) Immunizations and autism: a review of the literature. Can J Neurol Sci 33(4):341–346PubMedGoogle Scholar
  3. 3.
    Chen RT, Pless R, Destefano F (2001) Epidemiology of autoimmune reactions induced by vaccination. J Autoimmun 16(3):309–318. doi: 10.1006/jaut.2000.0491 PubMedCrossRefGoogle Scholar
  4. 4.
    Geier DA, Geier MR (2005) A case–control study of serious autoimmune adverse events following hepatitis B immunization. Autoimmunity 38(4):295–301PubMedCrossRefGoogle Scholar
  5. 5.
    Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700PubMedCrossRefGoogle Scholar
  6. 6.
    CDC (2010) Immunization schedule. Center for Disease Control and Prevention of the United States of America. Accessed 22 Aug 2010
  7. 7.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557–560. doi: 10.1136/bmj.327.7414.557 PubMedCrossRefGoogle Scholar
  8. 8.
    Takkouche B, Cadarso-Suarez C, Spiegelman D (1999) Evaluation of old and new tests of heterogeneity in epidemiologic meta-analysis. Am J Epidemiol 150(2):206–215PubMedGoogle Scholar
  9. 9.
    Andersen E, Isager H, Hyllested K (1981) Risk factors in multiple sclerosis: tuberculin reactivity, age at measles infection, tonsillectomy and appendectomy. Acta Neurol Scand 63(2):131–135PubMedCrossRefGoogle Scholar
  10. 10.
    Bansil S, Singhal BS, Ahuja GK, Riise T, Ladiwala U, Behari M, Cook SD (1997) Multiple sclerosis in India: a case–control study of environmental exposures. Acta Neurol Scand 95(2):90–95PubMedCrossRefGoogle Scholar
  11. 11.
    Berr C, Puel J, Clanet M, Ruidavets JB, Mas JL, Alperovitch A (1989) Risk factors in multiple sclerosis: a population-based case-control study in Hautes-Pyrénées, France. Acta Neurol Scand 80(1):46–50PubMedCrossRefGoogle Scholar
  12. 12.
    Casetta I, Granieri E, Malagù S, Tola MR, Paolino E, Caniatti LM, Govoni V, Monetti VC, Fainardi E (1994) Environmental risk factors and multiple sclerosis: a community-based, case-control study in the province of Ferrara, Italy. Neuroepidemiology 13(3):120–128PubMedCrossRefGoogle Scholar
  13. 13.
    Pekmezovic T, Jarebinski M, Drulovic J (2004) Childhood infections as risk factors for multiple sclerosis: Belgrade case–control study. Neuroepidemiology 23(6):285–288. doi: 10.1159/000080094 PubMedCrossRefGoogle Scholar
  14. 14.
    Zorzon M, Zivadinov R, Nasuelli D, Dolfini P, Bosco A, Bratina A, Tommasi MA, Locatelli L, Cazzato G (2003) Risk factors of multiple sclerosis: a case–control study. Neurol Sci 24(4):242–247. doi: 10.1007/s10072-003-0147-6 PubMedCrossRefGoogle Scholar
  15. 15.
    Kurtzke JF, Hyllested K, Arbuckle JD, Brønnum-Hansen H, Wallin MT, Heltberg A, Jacobsen H, Olsen A, Eriksen LS (1997) Multiple sclerosis in the Faroe Islands 7 Results of a case control questionnaire with multiple controls. Acta Neurol Scand 96(3):149–157PubMedCrossRefGoogle Scholar
  16. 16.
    DeStefano F, Verstraeten T, Jackson LA, Okoro CA, Benson P, Black SB, Shinefield HR, Mullooly JP, Likosky W, Chen RT, Vaccine Safety Datalink Research Group NIP, Centers for Disease Control, Prevention (2003) Vaccinations and risk of central nervous system demyelinating diseases in adults. Arch Neurol 60(4):504–509. doi: 10.1001/archneur.60.4.504 PubMedCrossRefGoogle Scholar
  17. 17.
    Ascherio A, Zhang SM, Hernán MA, Olek MJ, Coplan PM, Brodovicz K, Walker AM (2001) Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med 344(5):327–332PubMedCrossRefGoogle Scholar
  18. 18.
    Hernán MA, Jick SS, Olek MJ, Jick H (2004) Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study. Neurology 63(5):838–842PubMedGoogle Scholar
  19. 19.
    Hocine MN, Farrington CP, Touzé E, Whitaker HJ, Fourrier A, Moreau T, Tubert-Bitter P (2007) Hepatitis B vaccination and first central nervous system demyelinating events: reanalysis of a case-control study using the self-controlled case series method. Vaccine 25(31):5938–5943. doi: 10.1016/j.vaccine.2007.05.032 PubMedCrossRefGoogle Scholar
  20. 20.
    Ramagopalan SV, Valdar W, Dyment DA, DeLuca GC, Yee IM, Giovannoni G, Ebers GC, Sadovnick AD, Group CCS (2009) Association of infectious mononucleosis with multiple sclerosis. A population-based study. Neuroepidemiology 32(4):257–262. doi: 10.1159/000201564 PubMedCrossRefGoogle Scholar
  21. 21.
    Touzé E, Fourrier A, Rue-Fenouche C, Rondé-Oustau V, Jeantaud I, Bégaud B, Alpérovitch A (2002) Hepatitis B vaccination and first central nervous system demyelinating event: a case–control study. Neuroepidemiology 21(4):180–186PubMedCrossRefGoogle Scholar
  22. 22.
    Zipp F, Weil JG, Einhäupl KM (1999) No increase in demyelinating diseases after hepatitis B vaccination. Nat Med 5(9):964–965. doi: 10.1038/12376 PubMedCrossRefGoogle Scholar
  23. 23.
    Confavreux C, Suissa S, Saddier P, Bourdès V, Vukusic S, ViMSS Group (2001) Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group. N Engl J Med 344(5):319–326PubMedCrossRefGoogle Scholar
  24. 24.
    Bamford CR, Sibley WA, Laguna JF (1978) Swine influenza vaccination in patients with multiple sclerosis. Arch Neurol 35(4):242–243PubMedGoogle Scholar
  25. 25.
    Miller AE, Morgante LA, Buchwald LY, Nutile SM, Coyle PK, Krupp LB, Doscher CA, Lublin FD, Knobler RL, Trantas F, Kelley L, Smith CR, La Rocca N, Lopez S (1997) A multicenter, randomized, double-blind, placebo-controlled trial of influenza immunization in multiple sclerosis. Neurology 48(2):312–314PubMedGoogle Scholar
  26. 26.
    Mokhtarian F, Shirazian D, Morgante L, Miller A, Grob D, Lichstein E (1997) Influenza virus vaccination of patients with multiple sclerosis. Multiple Scler 3(4):243–247CrossRefGoogle Scholar
  27. 27.
    Myers LW, Ellison GW, Lucia M, Novom S (1976) Swine-influenza vaccination in multiple sclerosis. N Engl J Med 295(21):1204PubMedGoogle Scholar
  28. 28.
    Ahlgren C, Torén K, Odén A, Andersen O (2009) A population-based case–control study on viral infections and vaccinations and subsequent multiple sclerosis risk. Eur J Epidemiol 24(9):541–552. doi: 10.1007/s10654-009-9367-2 PubMedCrossRefGoogle Scholar
  29. 29.
    Zilber N, Kahana E (1996) Risk factors for multiple sclerosis: a case–control study in Israel. Acta Neurol Scand 94(6):395–403PubMedCrossRefGoogle Scholar
  30. 30.
    Compston DA, Vakarelis BN, Paul E, McDonald WI, Batchelor JR, Mims CA (1986) Viral infection in patients with multiple sclerosis and HLA-DR matched controls. Brain 109(Pt 2):325–344PubMedCrossRefGoogle Scholar
  31. 31.
    Alter M, Speer J (1968) Clinical evaluation of possible etiologic factors in multiple sclerosis. Neurology 18(2):109–116PubMedGoogle Scholar
  32. 32.
    Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH, Harbour RT, Haugh MC, Henry D, Hill S, Jaeschke R, Leng G, Liberati A, Magrini N, Mason J, Middleton P, Mrukowicz J, O’Connell D, Oxman AD, Phillips B, Schünemann HJ, Edejer TT-T, Varonen H, Vist GE, Williams JW, Zaza S, Group GW (2004) Grading quality of evidence and strength of recommendations. BMJ 328(7454):1490. doi: 10.1136/bmj.328.7454.1490
  33. 33.
    Weiner HL (2009) The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease? Ann Neurol 65(3):239–248. doi: 10.1002/ana.21640 PubMedCrossRefGoogle Scholar
  34. 34.
    Ramagopalan SV, Dobson R, Meier UC, Giovannoni G (2010) Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurol 9(7):727–739. doi: 10.1016/S1474-4422(10)70094-6 PubMedCrossRefGoogle Scholar
  35. 35.
    Baranzini SE, Mudge J, van Velkinburgh JC, Khankhanian P, Khrebtukova I, Miller NA, Zhang L, Farmer AD, Bell CJ, Kim RW, May GD, Woodward JE, Caillier SJ, McElroy JP, Gomez R, Pando MJ, Clendenen LE, Ganusova EE, Schilkey FD, Ramaraj T, Khan OA, Huntley JJ, Luo S, Kwok P-Y, Wu TD, Schroth GP, Oksenberg JR, Hauser SL, Kingsmore SF (2010) Genome, epigenome and RNA sequences of monozygotic twins discordant for multiple sclerosis. Nature 464(7293):1351–1356. doi: 10.1038/nature08990 PubMedCrossRefGoogle Scholar
  36. 36.
    Hernán MA, Olek MJ, Ascherio A (1999) Geographic variation of MS incidence in two prospective studies of US women. Neurology 53(8):1711–1718PubMedGoogle Scholar
  37. 37.
    Munger KL, Zhang SM, O’Reilly E, Hernán MA, Olek MJ, Willett WC, Ascherio A (2004) Vitamin D intake and incidence of multiple sclerosis. Neurology 62(1):60–65PubMedGoogle Scholar
  38. 38.
    Hernán MA, Jick SS, Logroscino G, Olek MJ, Ascherio A, Jick H (2005) Cigarette smoking and the progression of multiple sclerosis. Brain 128(Pt 6):1461–1465. doi: 10.1093/brain/awh471 PubMedCrossRefGoogle Scholar
  39. 39.
    Ascherio A, Munger KL (2007) Environmental risk factors for multiple sclerosis. Part I. The role of infection. Ann Neurol 61(4):288–299. doi: 10.1002/ana.21117 PubMedCrossRefGoogle Scholar
  40. 40.
    Correale J, Fiol M, Gilmore W (2006) The risk of relapses in multiple sclerosis during systemic infections. Neurology 67(4):652–659. doi: 10.1212/01.wnl.0000233834.09743.3b PubMedCrossRefGoogle Scholar
  41. 41.
    Buljevac D, Flach HZ, Hop WCJ, Hijdra D, Laman JD, Savelkoul HFJ, van Der Meché FGA, van Doorn PA, Hintzen RQ (2002) Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain 125(Pt 5):952–960PubMedCrossRefGoogle Scholar
  42. 42.
    Correale J, Farez M (2007) Association between parasite infection and immune responses in multiple sclerosis. Ann Neurol 61(2):97–108. doi: 10.1002/ana.21067 PubMedCrossRefGoogle Scholar
  43. 43.
    Hernán MA, Alonso A, Hernández-Díaz S (2006) Tetanus vaccination and risk of multiple sclerosis: a systematic review. Neurology 67(2):212–215. doi: 10.1212/01.wnl.0000225079.51201.f9 PubMedCrossRefGoogle Scholar
  44. 44.
    Hill AB (1965) The environment and disease: association or causation? Proc R Soc Med 58:295–300PubMedGoogle Scholar
  45. 45.
    Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M (2007) Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med 4(10):e297PubMedCrossRefGoogle Scholar
  46. 46.
    Lau J, Antman EM, Jimenez-Silva J, Kupelnick B, Mosteller F, Chalmers TC (1992) Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med 327(4):248–254. doi: 10.1056/NEJM199207233270406 PubMedCrossRefGoogle Scholar
  47. 47.
    Cabrera-Gómez JA, Echazabal-Santana N, García-González L, Ramos-Cedeño AM, Rodríguez-Roque MO, López-Hernández O, Cabrera-Núñez JA, De González La Nuez J, Téllez L (2002) A severe episode in a patient with recurrent disseminated acute encephalitis due to vaccination against hepatitis B. For or against vaccination? Rev Neurol 34(4):358–363PubMedGoogle Scholar
  48. 48.
    Chaves M, Riccio P, Patrucco L, Rojas J, Cristiano E (2009) Longitudinal myelitis associated with yellow fever vaccination. J Neurovirol 15(4):348–350. doi: 10.1080/13550280903062805 Google Scholar
  49. 49.
    Miller H, Cendrowski W, Shapira K (1967) Multiple sclerosis and vaccination. Br Med J 2(5546):210–213PubMedCrossRefGoogle Scholar
  50. 50.
    Sutton I, Lahoria R, Tan I, Clouston P, Barnett M (2009) CNS demyelination and quadrivalent HPV vaccination. Multiple Scler 15(1):116–119. doi: 10.1177/1352458508096868 CrossRefGoogle Scholar
  51. 51.
    Terney D, Beniczky S, Barsi P, Kondákor I, Perényi J, Faludi B, Szapper M, Vécsei L (2006) Multiple sclerosis after hepatitis B vaccination in a 16-year-old patient. Chin Med J 119(1):77–79PubMedGoogle Scholar
  52. 52.
    Wildemann B, Jarius S, Hartmann M, Regula JU, Hametner C (2009) Acute disseminated encephalomyelitis following vaccination against human papilloma virus. Neurology 72(24):2132–2133. doi: 10.1212/WNL.0b013e3181aa53bb PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  1. 1.Department of NeurologyDr Raúl Carrea Institute for Neurological Research, FLENIBuenos AiresArgentina

Personalised recommendations